Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Follow-Up Questions
CDIO 주식의 가격 성능은 어떻습니까?
CDIO의 현재 가격은 $4.5이며, 전 거래일에 increased 0.34% 하였습니다.
Cardio Diagnostics Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
Cardio Diagnostics Holdings Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Cardio Diagnostics Holdings Inc의 시가총액은 얼마입니까?
Cardio Diagnostics Holdings Inc의 현재 시가총액은 $7.9M입니다
Cardio Diagnostics Holdings Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Cardio Diagnostics Holdings Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
